Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux (biopsy I)
Primary Purpose
Larynx Disease, Gastroesophageal Reflux
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Esophageal and Laryngeal biopsies
egd with biopsy
Sponsored by
About this trial
This is an interventional diagnostic trial for Larynx Disease
Eligibility Criteria
Inclusion Criteria
- GERD 1. Documented erosive esophagitis (Patients will be newly diagnosed with esophageal erosion at initial visit via esophagogastroduodenoscopy [EGD]) 2.Patients with non-erosive esophagitis who have been responsive to PPI
- LPR 1. Diagnosed via Head & Neck Institute endoscopists (i.e. patients will be newly diagnosed at initial visit via laryngoscopy)
Controls
- No complaints or history of heartburn, acid regurgitation, atypical chest pain
- Never been seen by GI or ENT for related symptoms
- No prior therapy for GERD
- Have a medical condition other than reflux for which they need to undergo EGD. These conditions can be diarrhea, peptic ulcer disease, malabsorption, anemia, and dysphagia.
Exclusion Criteria
- Age < 18yrs
- Pregnancy
- Patients with contra-indications for EGD
- Use of antacid (PPI, H2RB) within last 30 days
- Use of any/all medications affecting gastrointestinal motility
- Known history of: Barrett's esophagus, Peptic stricture, Pyloric stenosis, Gastric resection
- Patients unable to give informed consent
- Patients unable to comply with follow-up
- Contraindications to biopsy: Taking anticoagulants other than aspirin (Coumadin, Plavix) or allergies to local anesthetic.
Sites / Locations
- Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410
Outcomes
Primary Outcome Measures
Dilation of intracellular spaces at the beginning of the study
Secondary Outcome Measures
Full Information
NCT ID
NCT00373997
First Posted
September 5, 2006
Last Updated
April 29, 2014
Sponsor
Vanderbilt University
1. Study Identification
Unique Protocol Identification Number
NCT00373997
Brief Title
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
Acronym
biopsy I
Official Title
Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to determine whether patients with suspected Laryngopharyngeal reflux have inflammation and ultrastructural injury on their laryngeal biopsies.
Detailed Description
Gastroesophageal reflux disease (GERD) has been implicated, in part, as the cause of various laryngeal signs and symptoms (1-7). This is often termed reflux laryngitis, ear, nose, and throat (ENT) reflux, or laryngopharyngeal reflux (LPR). GERD was first described to be a causative agent in developing contact ulcers of the larynx (8), and since this early report other routinely observed laryngeal signs are now attributed to LPR. These include laryngeal edema/erythema, vocal cord granulomas and polyps, posterior cricoid cobblestoning, interarytenoid changes, and subglottic stenosis. In addition, patient symptoms attributed to LPR include hoarseness, sore or burning throat, chronic cough, throat clearing, globus, nocturnal laryngospasm, otalgia, post-nasal drip, and dysphagia.
GERD occurs in 7% - 25% of the population on a daily or monthly basis, respectively (9). It is estimated that up to 10% of patients presenting to ENT physicians do so because of complaints that are thought to be related to LPR (2).
The current management of patients with suspected LPR complaints include either 1. empiric therapy using proton pump inhibitors (PPI's) or 2. Ambulatory 24hour pH monitoring to test for GERD before beginning treatment. Because of the uncertainty and subjectivity of the ENT laryngeal examination in diagnosing LPR, both algorithms fall short of ideal in treating these patients. In a recent review of the literature, remarkably, up to 50% of patients with laryngoscopic signs suggesting LPR do not respond to aggressive acid suppression and do not have abnormal esophageal acid reflux values on pH testing (10). Yet, in this subset of patients LPR continues to be implicated as the probable etiology of the patients laryngeal signs and symptoms.
Calabrese, et al. recently looked at the reversibility of GERD related ultrastructural alterations in the esophagus using a PPI. Lower esophageal biopsies were analyzed with electron microscopy (EM) for ultrastructural alterations attributed to GERD; that is, dilation of intracellular spaces. Patients were then treated with a PPI and re-biopsied for analysis of any changes of healing that may have occurred in these ultrastructural alterations. Not surprisingly, the ultrastructural alterations showed complete recovery (reduction of dilated intracellular spaces) after treatment with a PPI. Additionally resolution of patients symptoms coincided with recovery of ultrastructural alterations (11). No such biopsies looking for LPR related changes in the larynx have ever been performed in human subjects.
In sum, LPR is an extremely subjective diagnosis, in which nearly half of all patients do not have an abnormal 24hr pH study, nor do they respond to the standard GERD therapy of acid suppression. Finding an alternative objective criterion for GERD induced laryngitis would be an important clinical discovery. To date, there are no data on microscopic changes in the larynx of patients suspected of having LPR.
In sum, LPR is an extremely subjective diagnosis, in which nearly half of all patients do not have an abnormal 24hr pH study, nor do they respond to the standard GERD therapy of acid suppression. To date, there is no microscopic evidence of laryngeal damage caused by LPR.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Larynx Disease, Gastroesophageal Reflux
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Esophageal and Laryngeal biopsies
Other Intervention Name(s)
esophagogastroduodenoscopy
Intervention Description
one day procedure
Intervention Type
Procedure
Intervention Name(s)
egd with biopsy
Other Intervention Name(s)
esophagogastroduodenoscopy
Intervention Description
standard of care procedure with biopsy
Primary Outcome Measure Information:
Title
Dilation of intracellular spaces at the beginning of the study
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
GERD 1. Documented erosive esophagitis (Patients will be newly diagnosed with esophageal erosion at initial visit via esophagogastroduodenoscopy [EGD]) 2.Patients with non-erosive esophagitis who have been responsive to PPI
LPR 1. Diagnosed via Head & Neck Institute endoscopists (i.e. patients will be newly diagnosed at initial visit via laryngoscopy)
Controls
No complaints or history of heartburn, acid regurgitation, atypical chest pain
Never been seen by GI or ENT for related symptoms
No prior therapy for GERD
Have a medical condition other than reflux for which they need to undergo EGD. These conditions can be diarrhea, peptic ulcer disease, malabsorption, anemia, and dysphagia.
Exclusion Criteria
Age < 18yrs
Pregnancy
Patients with contra-indications for EGD
Use of antacid (PPI, H2RB) within last 30 days
Use of any/all medications affecting gastrointestinal motility
Known history of: Barrett's esophagus, Peptic stricture, Pyloric stenosis, Gastric resection
Patients unable to give informed consent
Patients unable to comply with follow-up
Contraindications to biopsy: Taking anticoagulants other than aspirin (Coumadin, Plavix) or allergies to local anesthetic.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael F Vaezi, MD, PhD, MS epi
Organizational Affiliation
Vanderbilt University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-5280
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
We'll reach out to this number within 24 hrs